CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy

被引：34

作者：

Sone, Kazuki ^{[1
]}

Oguri, Tetsuya ^{[1
]}

Nakao, Makoto ^{[2
]}

Kagawa, Yusuke ^{[2
]}

Kurowaka, Ryota ^{[2
]}

Furuta, Hiromi ^{[3
]}

Fukuda, Satoshi ^{[1
]}

Uemura, Takehiro ^{[1
]}

Takakuwa, Osamu ^{[1
]}

Kanemitsu, Yoshihiro ^{[1
]}

Ohkubo, Hirotsugu ^{[1
]}

Takemura, Masaya ^{[1
]}

Maeno, Ken ^{[1
]}

Ito, Yutaka ^{[1
]}

Sato, Hidefumi ^{[2
]}

Muramatsu, Hideki ^{[2
]}

Niimi, Akio ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan

[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Co, Dept Resp Med, Yatomi, Japan

[3] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 02期

关键词：

Cytokeratin; 19; fragment; tumor marker; pemetrexed; non-squamous non-small cell lung cancer; PHASE-III; EFFICACY; CISPLATIN; FRAGMENT;

D O I：

10.21873/anticanres.11402

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: Pretreatment serum tumor marker levels predict outcome in non-small cell lung cancer (NSCLC). However, little is known about the clinical value of such measurements for patients treated with pemetrexed plus a platinum-derivative. Patients and Methods: We retrospectively screened 100 chemotherapy-naive patients with advanced non-squamous NSCLC treated with pemetrexed plus a platinum-derivative in relation to the pretreatment level of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA). Results: Sixty one patients with a high CYFRA 21-1 level had statistically shorter progression-free and overall survival than 39 patients with a normal CYFRA 21-1 level (median progression-free survival=127 days vs. 191 days, respectively; p=0.046; median overall survival=360 days vs. 781 days, respectively, p<0.001). Serum CEA level was not related to survival. Conclusion: Serum CYFRA 21-1 level is a predictive and prognostic marker in patients with NSCLC treated with pemetrexed plus a platinum-derivative.

引用

页码：935 / 939

页数：5

共 17 条

[1]

Cell type accuracy of bronchial biopsy specimens in primary lung cancer [J].

Cataluna, JJS ;

Perpina, M ;

Greses, JV ;

Calvo, V ;

Padilla, JD ;

Paris, F .

CHEST, 1996, 109 (05) :1199-1203

[2]

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non-Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304 [J].

Edelman, Martin J. ;

Hodgson, Lydia ;

Rosenblatt, Paula Y. ;

Christenson, Robert H. ;

Vokes, Everett E. ;

Wang, Xiaofei ;

Kratzke, Robert .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (04) :649-654

[3]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4]

Fiala O, 2016, ANTICANCER RES, V36, P461

[5]

Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

[6]

Kulpa J, 2002, CLIN CHEM, V48, P1931

[7]

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, Luis G. ;

de Marinis, Filippo ;

Dediu, Mircea ;

Thomas, Michael ;

Pujol, Jean-Louis ;

Bidoli, Paolo ;

Molinier, Olivier ;

Sahoo, Tarini Prasad ;

Laack, Eckart ;

Reck, Martin ;

Corral, Jesus ;

Melemed, Symantha ;

John, William ;

Chouaki, Nadia ;

Zimmermann, Annamaria H. ;

Visseren-Grul, Carla ;

Gridelli, Cesare .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2895-+

[8]

PUJOL JL, 1993, CANCER RES, V53, P61

[9]

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer:: results of a meta-analysis in 2063 patients [J].

Pujol, L ;

Molinier, O ;

Ebert, W ;

Daurès, JP ;

Barlesi, F ;

Buccheri, G ;

Paesmans, M ;

Quoix, E ;

Moro-Sibilot, D ;

Szturmowicz, M ;

Bréchot, JM ;

Muley, T ;

Grenier, J .

BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2097-2105

[10]

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer [J].

Rodrigues-Pereira, Jose ;

Kim, Joo-Hang ;

Magallanes, Manuel ;

Lee, Dae Ho ;

Wang, Jie ;

Ganju, Vinod ;

Martinez-Barrera, Luis ;

Barraclough, Helen ;

van Kooten, Maximiliano ;

Orlando, Mauro .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) :1907-1914

← 1 2 →